Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies
New Bruton’s tyrosine kinase (BTK) inhibitors caused drastic modifications in the therapy of chronic lymphocytic leukemia (CLL). Ibrutinib, the first in its class BTK inhibitor, showed high efficacy in many clinical studies. However, the treatment with BTK inhibitors as monotherapy must not be disco...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Russo |
| 出版事項: |
Practical Medicine Publishing House
2023-01-01
|
| シリーズ: | Клиническая онкогематология |
| 主題: | |
| オンライン･アクセス: | https://bloodjournal.ru/index.php/coh/article/view/5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|